News
Rugonersen Phase 1 TANGELO Study Results Published in Nature Medicine
July 11, 2025
Share
Oak Hill Bio announced the publication of rugonersen Phase 1 TANGELO study results in Nature Medicine.
The study provides evidence of improvement in brain activity and developmental ability in children with Angelman syndrome compared to natural history.
“These are promising results that mark a major milestone in the development of disease-modifying therapies for Angelman syndrome,” said Dr. Mark Shen, one of the principal investigators and authors of the paper.
Read the Community Summary here.
